Literature DB >> 27408517

Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Shannon Eaves, Jose A Rey.   

Abstract

Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder.

Entities:  

Year:  2016        PMID： 27408517      PMCID： PMC4927015     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  7 in total

1.  A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.

Authors:  John M Kane; Aleksandar Skuban; John Ouyang; Mary Hobart; Stephanie Pfister; Robert D McQuade; Margaretta Nyilas; William H Carson; Raymond Sanchez; Hans Eriksson
Journal:  Schizophr Res       Date:  2015-02-12       Impact factor: 4.939

2.  Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Christoph U Correll; Aleksandar Skuban; John Ouyang; Mary Hobart; Stephanie Pfister; Robert D McQuade; Margaretta Nyilas; William H Carson; Raymond Sanchez; Hans Eriksson
Journal:  Am J Psychiatry       Date:  2015-04-16       Impact factor: 18.112

3.  Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Authors:  Michael E Thase; James M Youakim; Aleksandar Skuban; Mary Hobart; Carole Augustine; Peter Zhang; Robert D McQuade; William H Carson; Margaretta Nyilas; Raymond Sanchez; Hans Eriksson
Journal:  J Clin Psychiatry       Date:  2015-09       Impact factor: 4.384

4.  Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.

Authors:  Michael E Thase; James M Youakim; Aleksandar Skuban; Mary Hobart; Peter Zhang; Robert D McQuade; Margaretta Nyilas; William H Carson; Raymond Sanchez; Hans Eriksson
Journal:  J Clin Psychiatry       Date:  2015-09       Impact factor: 4.384

5.  Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.

Authors:  Kenji Maeda; Haruhiko Sugino; Hitomi Akazawa; Naoki Amada; Jun Shimada; Takashi Futamura; Hiroshi Yamashita; Nobuaki Ito; Robert D McQuade; Arne Mørk; Alan L Pehrson; Morten Hentzer; Vibeke Nielsen; Christoffer Bundgaard; Jørn Arnt; Tine Bryan Stensbøl; Tetsuro Kikuchi
Journal:  J Pharmacol Exp Ther       Date:  2014-06-19       Impact factor: 4.030

6.  Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.

Authors:  Kenji Maeda; Linda Lerdrup; Haruhiko Sugino; Hitomi Akazawa; Naoki Amada; Robert D McQuade; Tine Bryan Stensbøl; Christoffer Bundgaard; Jørn Arnt; Tetsuro Kikuchi
Journal:  J Pharmacol Exp Ther       Date:  2014-06-19       Impact factor: 4.030

7.  Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization.

Authors:  Chris A Oosterhof; Mostafa El Mansari; Pierre Blier
Journal:  J Pharmacol Exp Ther       Date:  2014-09-15       Impact factor: 4.030
  7 in total
  4 in total

Review 1.  New Antipsychotic Medications in the Last Decade.

Authors:  Mehak Pahwa; Ahmad Sleem; Omar H Elsayed; Megan Elizabeth Good; Rif S El-Mallakh
Journal:  Curr Psychiatry Rep       Date:  2021-11-29       Impact factor: 5.285

2.  A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?

Authors:  Edem K Onyameh; Barbara A Bricker; Suresh V K Eyunni; Chandrashekhar Voshavar; Uma M Gonela; Edward Ofori; Andrea Jenkins; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2020-12-14       Impact factor: 3.641

3.  A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.

Authors:  Cynthia Richards; Dan V Iosifescu; Rajnish Mago; Elias Sarkis; Brooke Geibel; Matthew Dauphin; Roger S McIntyre; Richard Weisler; Olga Brawman-Mintzer; Joan Gu; Manisha Madhoo
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

4.  Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.

Authors:  Tingjian Yan; Mallik Greene; Eunice Chang; Christy R Houle; Marian H Tarbox; Michael S Broder
Journal:  Clinicoecon Outcomes Res       Date:  2020-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.